Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

2018-04-05

Additional Metadata
Persistent URL	doi.org/10.1080/10428194.2018.1452215, hdl.handle.net/1765/105762
Journal	Leukemia and Lymphoma
Organisation	Department of Public Health
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	van der Straten, L. (Lina), Dinmohamed, A., Westerweel, J., Langerak, A., Riedl, J., Doorduijn, J., … Levin, M.-D. (2018). Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia and Lymphoma, 1–5. doi:10.1080/10428194.2018.1452215

Publication